Trial · NCT06025409
Evaluate the Efficacy and Safety of DWJ108J
NCT06025409, Phase 3, Unknown, Daewoong Pharmaceutical Co. LTD.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluate the Efficacy and Safety of DWJ108J. Trials, record NCT06025409. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06025409
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluate the Efficacy and Safety of DWJ108J
- NCT number
- NCT06025409
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 79 participants, estimated
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
- Conditions
- Central Precocious Puberty
- Interventions
- Leuprolide Acetate 11.25 MG/ML
- First posted
- 2023-09-06
- Last updated
- 2023-09-06
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months. | 6 months | Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH ≤ 3 IU/L. |
| Secondary | Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 3 Months. | 3 months | Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH ≤ 3 IU/L. |
| Secondary | Average LH and FSH concentrations at each time point, and the changes from baseline levels before administration. | Baseline, 3 and 6 months | Average LH and FSH concentrations at each time point, and the changes from baseline levels before administration. |
| Secondary | Average LH peak and FSH peak through GnRH stimulation test at 3 and 6 months after administration, and the changes in each time point compared to before administration | 3 and 6 months | Average LH peak and FSH peak through GnRH stimulation test at 3 and 6 months after administration, and the changes in each time point compared to before administration |
| Secondary | Average concentrations of Estradiol or Testosterone at each time point, and the respective changes compared to before administration. | Baseline, 3 and 6 months | Average concentrations of Estradiol or Testosterone at each time point, and the respective changes compared to before administration. |
| Secondary | Average bone age/chronological age ratio at 6 months after administration, and the changes compared to before administration. | 6 months | Average bone age/chronological age ratio at 6 months after administration, and the changes compared to before administration. |
| Secondary | Average Tanner Stage at 6 months after administration, and the changes compared to before administration. | 6 months | Average Tanner Stage at 6 months after administration, and the changes compared to before administration. |
| Secondary | Average growth velocity (cm/year, annualized height velocity) at 6 months after administration, and the changes compared to before administration. | 6 months | Average growth velocity (cm/year, annualized height velocity) at 6 months after administration, and the changes compared to before administration. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06025409
GET https://conductscience.org/api/trials/v1/NCT06025409/registered